© Reuters. The emblem of the Spanish prescribed drugs firm Grifols is pictured on theirs amenities in Parets del Valles, north of Barcelona, Spain, January 9, 2024. REUTERS/Albert Gea
MADRID (Reuters) – Spanish pharma firm Grifols mentioned on Wednesday it would launch authorized motion in opposition to short-seller fund Gotham Metropolis Analysis which launched a adverse report that wiped nearly $3 billion off the Barcelona-based agency’s market worth on Tuesday.
Grifols will search monetary compensation in courtroom for the reputational harm, it mentioned in an announcement.